LifeStance Health Group (NASDAQ:LFST) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded LifeStance Health Group from “strong buy” to “buy,” though analysts maintain a consensus “Moderate Buy” rating with an average price target of $12.38.
• LifeStance exceeded quarterly expectations, reporting $0.06 EPS versus the $0.03 consensus and revenue of $435.35 million, up 26.1% year over year.
• Insiders sold approximately 14.7 million shares worth $155.5 million over the past 90 days, while institutional investors own 85.5% of the company.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on the company. Barclays upped their target price on LifeStance Health Group from $9.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 14th. BTIG Research lifted their target price on shares of LifeStance Health Group from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, August 19th. JPMorgan Chase & Co. upped their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Weiss Ratings raised shares of LifeStance Health Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 11th. Finally, Zacks Research cut LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $12.38.

LifeStance Health Group Trading Down 0.8%

Shares of LifeStance Health Group stock opened at $12.73 on Friday. LifeStance Health Group has a 52-week low of $4.77 and a 52-week high of $13.15. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a 50-day moving average of $11.49 and a 200-day moving average of $8.80. The stock has a market cap of $4.94 billion, a PE ratio of 97.93 and a beta of 1.22.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The firm had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business's revenue was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.01) EPS. As a group, sell-side analysts forecast that LifeStance Health Group will post 0.16 EPS for the current year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 44,394 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the sale, the chief technology officer directly owned 247,446 shares of the company's stock, valued at $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Lisa K. Miller sold 47,912 shares of LifeStance Health Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the sale, the chief operating officer directly owned 281,289 shares of the company's stock, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 14,671,917 shares of company stock worth $155,493,415 in the last ninety days. Corporate insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LFST. Larson Financial Group LLC grew its position in shares of LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company's stock valued at $27,000 after purchasing an additional 3,791 shares in the last quarter. KBC Group NV bought a new position in shares of LifeStance Health Group during the 1st quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its position in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock valued at $44,000 after acquiring an additional 5,404 shares during the last quarter. PNC Financial Services Group Inc. raised its position in LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock worth $59,000 after purchasing an additional 7,987 shares during the period. Finally, Assetmark Inc. increased its holdings in shares of LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company's stock worth $60,000 after buying an additional 1,367 shares during the period. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source